Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CeLEBrATE trial of carboplatin + etoposide + bevacizumab + atezolizumab in extended-disease small-cell lung cancer
2019-003798-25Phase 2Completed
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- Jan 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, atezolizumab, carboplatin and etoposide in small cell lung cancer (SCLC) and Lung neuroendocrine carcinoma (LNEC), sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Primary endpoints: Overall survival and 1-year cumulative survival rate. Started Jan 2021; status: completed.
02
Drugs
bevacizumabatezolizumabcarboplatinetoposide
03
Conditions
small cell lung cancer (SCLC)Lung neuroendocrine carcinoma (LNEC)
Beyond the preview
Go deeper on 2019-003798-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003798-25.